Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiolo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Infect Dis
Glavni autori: Shields, Ryan K., Potoski, Brian A., Haidar, Ghady, Hao, Binghua, Doi, Yohei, Chen, Liang, Press, Ellen G., Kreiswirth, Barry N., Clancy, Cornelius J., Nguyen, M. Hong
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Brief Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5146720/
https://ncbi.nlm.nih.gov/pubmed/27624958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciw636
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items